Ranking Profile - Catabasis Pharmaceuticals Inc

Introduction

Astria Therapeutics Inc (Astria), formerly Catabasis Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company. The company discovers, develops and commercializes medicines for the treatment of multiple diseases. It develops its product candidates using its proprietary safely metabolized and rationally targeted (SMART) Linker drug discovery platform for rare diseases, among others. Astria product candidate edasalonexent CAT-1004, currently under Phase 3 trial, is an oral small molecule intended for the treatment of Duchenne muscular dystrophy. CAT-5571, an activator of autophagy and the company’s lead product under preclinical stage, is an oral small molecule for the treatment of cystic fibrosis. The company’s CAT-4001 is used for the treatment of neurodegenerative diseases such as Friedreich's ataxia and amyotrophic lateral sclerosis (ALS). Astria is headquartered in Cambridge, Massachusetts, the US